SCHEMBL3498274

SCHEMBL3498274

CCOC(=O)c1cc2cc(-c3ccsc3)ccc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.50
DBF4 Q9UBU7 2/20 0.50
CHEK2 O96017 1/20 0.48
F9 P00740 2/20 0.46
F10 P00742 2/20 0.46
MAPT P10636 4/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
ALOX15 P16050 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PTPN2 P17706 2/20 0.44
ALDH1A1 P00352 1/20 0.44
PKM P14618 1/20 0.44
MAPK14 Q16539 1/20 0.41
GAA P10253 1/20 0.40
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500033 0.84 MAPT (0.56) F9F10MAPTMEN1KMT2A
SCHEMBL3498021 0.82 MAPT (0.50) F9F10MAPTPTPN2ALDH1A1
SCHEMBL3498454 0.82 MAPK14 (0.54) F9F10MAPTHSD17B10PTPN2
SCHEMBL3498640 0.81 MAPT (0.52) F9F10MAPTMEN1KMT2A
SCHEMBL3496798 0.80 PRKCI (0.46) F9F10MAPTMEN1KMT2A
SCHEMBL3498323 0.80 ACMSD (0.55) CHEK2F9F10ERN1ACMSD
SCHEMBL3499196 0.79 MAPT (0.53) F9F10MAPTMEN1KMT2A
SCHEMBL1205380 0.78 PTPN2 (0.51) MAPTMEN1KMT2AHSD17B10PTPN2
SCHEMBL3500699 0.78 F9 (0.49) F9F10MAPTHSD17B10PTPN2
SCHEMBL3499504 0.78 F9 (0.47) F9F10MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 CDC7 1595/4885DBF4 3227/4885CHEK2 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.